Announcements
- Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
- Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
- Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
- Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
- Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
- Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
- Akari Therapeutics to Present at Emerging Growth Conference
More ▼
Key statistics
As of last trade Akari Therapeutics PLC (CLA:MUN) traded at 2.98, -36.86% below its 52-week high of 4.72, set on Aug 15, 2023.
52-week range
Open | 2.98 |
---|---|
High | 2.98 |
Low | 2.98 |
Bid | 3.00 |
Offer | 3.16 |
Previous close | 2.92 |
Average volume | 0.00 |
---|---|
Shares outstanding | 597.67k |
Free float | 531.50k |
P/E (TTM) | -- |
Market cap | 38.03m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jul 04 2024 07:03 BST.
More ▼